The treatment of painful osseous metastases with phosphorus-32-labeled phosphates.
32P orthophosphate administered in a wide range of activity reduces or relieves the pain from osteoblastic metastases in approximately 80% of patients treated. The efficacy of this agent is equal to that of newer agents and of wide field radiotherapy, as documented in a literature review of 28 series reporting the use of 32P orthophosphate over a 50-year period. There is no dose-response relationship between the activity of 32P given and the percentage of patients experiencing pain reduction who received that activity. Only one death has been attributed to this radiopharmaceutical.
Silberstein
E B
EB
Department of Radiology, University of Cincinnati Medical Center, OH 45267.
D000315:Adrenalectomy; D001859:Bone Neoplasms / Q000378:metabolism / Q000532:radiotherapy* / Q000556:secondary* / Q000601:surgery; D006801:Humans; D010166:Palliative Care; D010710:Phosphates / Q000493:pharmacokinetics / Q000627:therapeutic use; D010761:Phosphorus Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011874:Radiometry
D010710:Phosphates; D010761:Phosphorus Radioisotopes